Corbus Pharmaceuticals Holdings, Inc.
Company Stats
- Market Cap
- $131.9M
- as of Sep 30, 2026
- Shares Outstanding
- 19.3M
- Free Float
- 84.5%
Income Statement
- Operating Income
- -$85.3M
- Net Income
- -$78.5M
- EBITDA
- -$85.1M
Cash Flow
- Free Cash Flow
- -$64.5M
- FCF Yield
- -48.9%
- Owner FCF Yield
- -53.7%
Balance Sheet
- Cash & Equivalents
- $28.5M
Returns & Capital
- SBC, 3Y Avg
- $5.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$64.5M | — |
| FY2024 | — | -$41.8M | — |
| FY2023 | — | -$36.1M | — |
| FY2022 | $0 | -$37.6M | — |
| FY2021 | $881,705 | -$48.2M | -5471.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 16, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
GLP-1 companies reshape access and detail treatment dropouts
Stronger demand supports expansion as pricing diverges